• Hippo Modules Direct Hepatobiliary Maturation

  2026-09-16

  This preprint identifies HPO1 and HPO2 as spatially and temporally distinct Hippo pathway modules that regulate hepatocyte and cholangiocyte maturation in mouse liver. Its combination of genetic perturbation, spatial transcriptomics, and imaging reframes Hippo signaling as a set of developmental checkpoints rather than only a general controller of organ size.

• Coronavirus Macrodomain–PARP Antagonism and IFN

  2026-09-15

  Grunewald et al. showed that coronavirus macrodomains counter host PARP-dependent ADP-ribosylation, allowing macrodomain-defective virus to evade replication restriction and impaired interferon induction. Pharmacologic inhibition and targeted depletion of PARP12 and PARP14 provide a framework for dissecting this host–virus pathway while distinguishing broad PARP effects from enzyme-specific mechanisms.

• PP 1: Src Family Tyrosine Kinase Inhibitor Workflow

  2026-09-15

  Build reproducible cancer and immunology assays around PP 1, a nanomolar Src family tyrosine kinase inhibitor for Lck, Fyn, and related signaling studies. This workflow connects phospho-signaling measurements, T-cell activation modulation, RET transformation models, and circRNA-driven prostate cancer research without overstating pathway causality.

• L-Phenylephrine: Reading α1A Signaling in Context

  2026-09-14

  L-Phenylephrine offers a precise way to interrogate adrenergic α1A receptor signaling beyond simple blood-pressure measurements. This article connects its pharmacology with telemetry, baroreflex analysis, sex-aware cardiovascular design, and assay interpretation.

• CNQX: AMPA/Kainate Receptor Antagonist

  2026-09-14

  CNQX, also known as 6-cyano-7-nitroquinoxaline-2,3-dione, is a competitive AMPA and kainate receptor antagonist used to isolate non-NMDA glutamatergic signaling. Its reported neuronal preparation IC50 values are 0.3 μM for AMPA receptors and 1.5 μM for kainate receptors, while a recent rat study used CNQX to distinguish AMPA/kainate signaling from NMDA-dependent cardiovascular responses.

• Plasmid Quality as a Lever in AML Research

  2026-09-13

  A mechanistic look at how reliable plasmid preparation can strengthen LMO2/LDB1 experiments in acute myeloid leukemia research, with strategic guidance for cloning, sequencing, perturbation, and translational validation.

• Cardiogreen Workflows for Imaging and PDT

  2026-09-12

  Cardiogreen, also known as Indocyanine green, connects near-infrared vascular imaging with a controllable photodynamic therapy workflow. Its plasma-protein binding supports vascular diagnostics, while carefully timed dye exposure and diode-laser treatment enable apoptosis-focused cell assays and mechanistic immunology studies.

• SOAT1, Lipophagy, and PHMG Pulmonary Fibrosis

  2026-09-11

  A 2026 Biochemical Pharmacology study identifies SOAT1 as a mechanistic link between PHMG exposure, cholesterol-ester accumulation, impaired lipophagy, and pro-fibrotic alveolar macrophage responses. Its in vivo and in vitro evidence supports SOAT1 inhibition with avasimibe as a preclinical strategy for limiting PHMG-associated pulmonary fibrosis.

• JHU-083 in Glutaminase Pathway Research

  2026-09-11

  JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway research in cerebral CD11b cells and experimental cerebral malaria models. This guide translates its mechanism into practical cell-based, biochemical, and neuroinflammation workflows while separating supported applications from exploratory extensions.

• IWR-1-endo: Wnt Signaling Inhibitor Workflows

  2026-09-10

  IWR-1-endo provides a practical way to suppress β-catenin accumulation in colorectal cancer and regenerative-model assays through Axin-scaffolded destruction complex stabilization. This guide combines formulation, dose-response, imaging, functional validation, and troubleshooting strategies for more reproducible Wnt pathway experiments.

• Methoxy-X04 and the Next Era of Amyloid Research

  2026-09-10

  Methoxy-X04 connects high-contrast amyloid imaging with emerging evidence that rTMS can influence microglial amyloid clearance through GABAergic neuron activation and the Cx3cl1-Cx3cr1 axis. This thought-leadership guide explains how translational researchers can use a fluorescent amyloid beta probe to distinguish intervention effects from static plaque measurements while preserving appropriate preclinical boundaries.

• Filipin III for Membrane Cholesterol Workflows

  2026-09-09

  Filipin III turns membrane-accessible cholesterol into a practical spatial readout for macrophage, vesicle, and membrane-fraction studies. This guide connects cholesterol imaging with the SOAT1–lipophagy axis implicated in PHMG-induced pulmonary fibrosis, while emphasizing controls, signal interpretation, and stability-aware handling.

• MOG (35-55): Practical EAE Research Workflow

  2026-09-09

  MOG (35-55) provides a defined myelin antigen for controlled EAE induction, cell-based neuroinflammation assays, and treatment-response studies. This workflow connects peptide preparation and dosing decisions with the STAT1/STAT2 biology highlighted in recent multiple sclerosis research.

• Firefly Luciferase mRNA: Workflow & Optimization

  2026-09-08

  Build sensitive gene expression, cell viability, and in vivo imaging assays around a stable, translationally optimized reporter. This guide connects practical Firefly Luciferase mRNA handling with nanoparticle-delivery lessons from a lung-targeting study, while separating validated product specifications from assay-starting recommendations.

• Cathepsin B inhibitor CA-074: Practical Guide

  2026-09-08

  CA-074 provides potent, selective inhibition of cathepsin B for separating CTSB-dependent proteolysis from broader cysteine-protease activity in biochemical, cellular, and disease-model workflows. It is appropriate for mechanistic research in cancer metastasis, neurotoxicity, and immune response modulation, but dossier potency values should not be treated as cell-based dosing, in vivo efficacy, or comprehensive off-target selectivity evidence.

8140 records 1/543 page Next 12345 下5页 Last page